Lung data give welcome boost to Boehringer's Gilotrif
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's Gilotrif (afatinib) has bested Astellas and Roche's Tarceva (erlotinib) in a Phase III study directly comparing the two therapies in advanced squamous cell carcinoma (SCC) of the lung.